Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.
Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.
Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
Private practice with Dr Seth BilazarianView all posts »
Pradaxa turns 19 (in dog years)Oct 23, 2012 10:30 EDT
As Pradaxa (dabigatran) celebrates its second anniversary since FDA approval, the clock is ticking to 2018, when its first patent is set to expire.
To download Dr Bilazarian's presentation, click here.
- New anticoagulants beat warfarin in AF meta-analysis
- Anticoagulation in AF: Fork in the road or four-way stop?
- Apixaban vs rivaroxaban vs dabigatran vs warfarin